History
  • No items yet
midpage
Louisiana Wholesale Drug Co. v. Shire LLC
754 F.3d 128
2d Cir.
2014
Read the full case

Background

  • Plaintiffs are wholesale pharmaceutical dealers who purchased unbranded AXR from Teva and Impax under Shire settlements.
  • Shire holds AXR patents; Teva and Impax sought FDA approval for generic AXR under Hatch-Waxman, triggering patent litigation actions.
  • In 2006, Shire settled with Teva and Impax; settlements required a three-year market abstention and granted licenses to Teva and Impax starting in 2009.
  • If FDA did not approve by that time, Shire would supply Teva's and Impax's needs for unbranded AXR for resale.
  • By 2009 Teva and Impax began purchasing unbranded AXR from Shire; later alleged shortfalls allegedly affected wholesale prices.
  • District court dismissed LWD’s complaint under Rule 12(b)(6); the dismissal was upheld on appeal.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Duty to deal under Aspen Skiing framework LWD says settlements removed patent barrier, creating duty to deal No duty to deal; terms do not resemble Aspen Skiing facts Aspen Skiing not satisfied; no duty to deal
Contracts with Teva/Impax as antitrust violation Breach of agreements harmed competition and created monopoly power Actions within patent regime immune from antitrust scrutiny No cognizable antitrust claim; breaches not enough
Effect of Actavis on Tamoxifen precedents Actavis abrogates Tamoxifen, broadening scrutiny Court did not rely on Actavis to decide; not controlling here Actavis not controlling; claim rejected on other grounds

Key Cases Cited

  • Tamoxifen Citrate Antitrust Litig., 466 F.3d 187 (2d Cir. 2006) (Tamoxifen invalidated by Actavis; reverse payments scrutinized)
  • Actavis, Inc. v. FTC, 133 S. Ct. 2223 (U.S. 2013) (reverse payments potentially anticompetitive; not immune under patent law)
  • Aspen Skiing Co. v. Aspen Highlands Skiing Corp., 472 U.S. 585 (U.S. 1985) (duty to deal where monopolist terminates a prior course of dealing)
  • United States v. Colgate & Co., 250 U.S. 300 (U.S. 1919) (long-recognized right to deal; exception only for terminating prior dealing)
  • Trinko, United States v., 540 U.S. 398 (U.S. 2004) (duty to deal limited; Aspen Skiing confines reach)
  • In re Elevator Antitrust Litig., 502 F.3d 47 (2d Cir. 2007) ( Aspen-like duty analysis; not controlling here)
  • Verizon Commc'ns Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398 (U.S. 2004) (antitrust need for anticompetitive conduct with monopoly power)
  • Pac. Bell Tel. Co. v. Linkline Commc'ns, Inc., 555 U.S. 438 (U.S. 2009) (distinction between regulation and antitrust duty to deal)
  • Brooke Grp. Ltd. v. Brown & Williamson Tobacco Corp., 509 U.S. 209 (U.S. 1993) (even malicious conduct alone does not state antitrust claim)
Read the full case

Case Details

Case Name: Louisiana Wholesale Drug Co. v. Shire LLC
Court Name: Court of Appeals for the Second Circuit
Date Published: Jun 19, 2014
Citation: 754 F.3d 128
Docket Number: 13–1232
Court Abbreviation: 2d Cir.